Ritonavir-Saquinavir Dual Protease Inhibitor Compared to Ritonavir Alone in Human Immunodeficiency Virus-Infected Patients

The objective of this study was to evaluate the antiretroviral efficacy and safety of ritonavir (600 mg twice a day [b.i.d.])-saquinavir (400 mg b.i.d.) compared to ritonavir (600 mg b.i.d.) in patients pretreated and receiving continued treatment with two nucleoside analogs. The study was placebo c...

Ausführliche Beschreibung

Bibliografische Detailangaben

Veröffentlicht in:	Antimicrob Agents Chemother
Hauptverfasser:	Michelet, Christian, Ruffault, Annick, Sébille, Véronique, Arvieux, Cedric, Jaccard, Philippe, Raffi, François, Bazin, Claude, Chapplain, Jean-Marc, Chauvin, Jean-Pierre, Dohin, Elisabeth, Cartier, François, Bellissant, Eric
Format:	Artigo
Sprache:	Inglês
Veröffentlicht:	American Society for Microbiology (ASM) 2001
Schlagworte:	Antiviral Agents
Online-Zugang:	https://ncbi.nlm.nih.govhttps://pmc.ncbi.nlm.nih.gov/articles/PMC90843/ https://ncbi.nlm.nih.govhttps://pubmed.ncbi.nlm.nih.gov/11709314/ https://ncbi.nlm.nih.govhttps://doi.org/10.1128/AAC.45.12.3393-3402.2001
Tags:	Tag hinzufügen Keine Tags, Fügen Sie das erste Tag hinzu!